Malignant News and Research

RSS

Experimental therapy has over 90% remission rate for advanced leukemia patients

Twenty-seven of 29 patients with an advanced type of leukemia that had proved resistant to multiple other forms of therapy went into remission after their T cells (disease-fighting immune cells) were genetically engineered to fight their cancers.

28 Apr 2016

New form of SBRT to deliver radiation to specific area of prostate cancer

University Hospitals Seidman Cancer Center physicians have started the world's first clinical trial using a new form of stereotactic body radiotherapy (SBRT) to deliver radiation to a specific area of the prostate invaded with cancer - instead of the entire gland. The study aims to determine if treating a targeted cancer region within the prostate in early stage prostate cancer can increase treatment options and reduce the side effects of radiation.

28 Apr 2016

Investigators explore possible causes for cancer recurrence after LRC

Although laparoscopic radical cystectomy (LRC) and robotic assisted radical cystectomy (RARC) continue to grow in popularity and are successful in the treatment of bladder cancer, they are still considered experimental approaches. Using data collected by the Section of Uro-Technology of the European Association of Urology (ESUT), a team of researchers found that about 5% of patients experienced unexpected relapses of cancer after LRC, even with favorable pathology.

27 Apr 2016

Protea signs license agreement with Yale to develop new technology for detecting malignant melanoma

Protea Biosciences Group, Inc. announced today that it had entered into an exclusive license agreement with Yale University for new technology to improve the differential diagnosis of malignant melanoma.

27 Apr 2016

Changes in chromatin structure may promote cancer

Cancer development is a complex process involving both genetic and epigenetic changes. Genetic changes in oncogenes and tumor-suppressor genes are generally considered as primary causes, since these genes may directly regulate cellular growth. In addition, it has been found that changes in epigenetic factors, through mutation or altered gene expression, may contribute to cancer development.

26 Apr 2016

New photo-switchable molecule for PDT could help treat rapidly growing tumors

Photoswitchable agents might reduce side effects of a chemotherapy. So far, photodynamic therapies have been dependent on oxygen in the tissue. But hardly any oxygen exists in malignant, rapidly growing tumors.

25 Apr 2016

Open source machine learning tools as good as humans in detecting cancer cases

Machine learning has come of age in public health reporting according to researchers from the Regenstrief Institute and Indiana University School of Informatics and Computing at Indiana University-Purdue University Indianapolis.

22 Apr 2016

Researchers reposition existing prazosin drug to combat glioblastoma

Treatments available for glioblastoma—malignant brain tumors—have little effect. An international collaboration led by the Laboratoire Neurosciences Paris-Seine tested active ingredients from existing medications and eventually identified one compound of interest, prazosin, on these tumors. Not only did it seem to be effective in this type of cancer, but it also acted on a signaling pathway that is common with other cancers.

21 Apr 2016

Cancer causing genetic condition risk in children lower than previously thought

The odds of children having a genetic condition which causes learning difficulties and tumours have been dramatically cut, thanks to genetic analysis led by The University of Manchester and Central Manchester University Hospitals NHS Foundation Trust

18 Apr 2016

First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

A rare malignancy known as squamous cell carcinoma of the anal canal (SCCA) is on the increase, and now researchers have reported results of the first-ever phase II clinical trial results for treatment with the immunotherapy drug nivolumab.

18 Apr 2016

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

In a small, phase I clinical trial, Johns Hopkins Kimmel Cancer Center researchers say they show for the first time that the experimental drug guadecitabine (SGI-110) is safe in combination with the chemotherapy drug irinotecan and may overcome resistance to irinotecan in patients with metastatic colorectal cancer.

18 Apr 2016

Survivin inhibitor with chemotherapy provides therapeutic advantage for Rb cells, tumors

Researchers at The Saban Research Institute of Children's Hospital Los Angeles (CHLA) have demonstrated that targeting survivin - a protein that inhibits apoptosis or cell death - enhances the effectiveness of chemotherapy in cells and mouse models of retinoblastoma (Rb), the most common malignant tumor of the eye in children.

18 Apr 2016

Study reveals TRPV2 protein as new target for chronic pain, cancer treatments

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length structure of a protein named Transient Receptor Potential Vanilloid subtype 2 (TRPV2).

13 Apr 2016

Six newly identified proteins may help potentially unlock new insights into aging-related diseases

A group of six newly discovered proteins may help to divulge secrets of how we age, potentially unlocking new insights into diabetes, Alzheimer's, cancer, and other aging-related diseases.

12 Apr 2016

Pericardial window operation not effective in lung cancer cases, say researchers

Pericardial window operation, a procedure, where abnormal quantity of malignant fluid, or malignant pericardial effusion (MPE), surrounding the heart, is drained into the neighbouring chest cavity through a surgically placed tube, is commonly applied to patients diagnosed with cancer.

12 Apr 2016

Alternative splicing regulates MALT1 protein to have stronger or weaker effect on immune system

The protein MALT1 is an important switch in immune cells and affects their activity. Researchers at Helmholtz Zentrum München report in 'Nature Communications' that this activation is not always equally strong. Through alternative splicing, two variants of the protein may arise which have a stronger or weaker effect on the immune system. Understanding this process is important for the pharmacological use of MALT1.

12 Apr 2016

Bonn mathematicians develop new model for cancer immunotherapy

Mathematicians and physicians at the University of Bonn have developed a new model for immunotherapy of cancer. The method could help to develop new treatment strategies and to understand why some approaches do not work with certain tumors. The study is now appearing in the technical journal "Scientific Reports".

12 Apr 2016

Study finds how tumour cells grow through scavenging bad cholesterol

Several studies have recognized a link between obesity and cancer. Richard Lehner, professor of Pediatrics and investigator at the University of Alberta's Faculty of Medicine & Dentistry, has taken his research further to understand how tumour cells grow through scavenging very low-density lipoproteins (VLDL) and low-density lipoproteins (LDL), commonly known as the "bad cholesterol", and what mechanisms can be used to reduce the malignant cells' growth.

11 Apr 2016

Researchers aim to improve current procedures for predicting outcome of prostate cancer

Researchers are working to find a way to determine how serious prostate cancer is when first diagnosed to avoid unnecessary treatments, which can cause life long side effects and even death.

6 Apr 2016

Certain malignant gastrointestinal stromal tumors more deadly than previously reported

Researchers at University of California, San Diego School of Medicine have determined that certain gastrointestinal stromal tumors (GISTs) are more deadly than previously reported in medical literature. Findings are published online in the Journal of Gastrointestinal Surgery.

6 Apr 2016

Malignant News and Research

Experimental therapy has over 90% remission rate for advanced leukemia patients

New form of SBRT to deliver radiation to specific area of prostate cancer

Investigators explore possible causes for cancer recurrence after LRC

Protea signs license agreement with Yale to develop new technology for detecting malignant melanoma

Changes in chromatin structure may promote cancer

New photo-switchable molecule for PDT could help treat rapidly growing tumors

Open source machine learning tools as good as humans in detecting cancer cases

Researchers reposition existing prazosin drug to combat glioblastoma

Cancer causing genetic condition risk in children lower than previously thought

First-ever nivolumab drug trial for rare, malignant SCCA shows positive results

Study shows safety of experimental drug guadecitabine in colorectal cancer patients

Survivin inhibitor with chemotherapy provides therapeutic advantage for Rb cells, tumors

Study reveals TRPV2 protein as new target for chronic pain, cancer treatments

Six newly identified proteins may help potentially unlock new insights into aging-related diseases

Pericardial window operation not effective in lung cancer cases, say researchers

Alternative splicing regulates MALT1 protein to have stronger or weaker effect on immune system

Bonn mathematicians develop new model for cancer immunotherapy

Study finds how tumour cells grow through scavenging bad cholesterol

Researchers aim to improve current procedures for predicting outcome of prostate cancer

Certain malignant gastrointestinal stromal tumors more deadly than previously reported

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News